These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 9184009)

  • 41. Phagocytosis and intracellular killing of Candida albicans blastoconidia by neutrophils and macrophages: a comparison of different microbiological test systems.
    Vonk AG; Wieland CW; Netea MG; Kullberg BJ
    J Microbiol Methods; 2002 Mar; 49(1):55-62. PubMed ID: 11777582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo determination of phagocytic indices and candidacidal activities of Candida species by rat peritoneal macrophages.
    Salim R; van Gelderen de Komaid A
    Mycopathologia; 1986 Jul; 95(1):17-23. PubMed ID: 3531869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae.
    van der Graaf CA; Netea MG; Verschueren I; van der Meer JW; Kullberg BJ
    Infect Immun; 2005 Nov; 73(11):7458-64. PubMed ID: 16239547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterisation of Candida albicans infections of haematogenous and mucosal origin in mice lacking the interferon gamma receptor protein.
    Londono LP; Jones HB; Vie AT; McPheat WL; Booth G; Gao XM; Dougan G
    FEMS Immunol Med Microbiol; 2000 Feb; 27(2):117-25. PubMed ID: 10640606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunosuppressive effect of cyclosporin A on resistance to systemic infection with Candida albicans.
    Vecchiarelli A; Cenci E; Marconi P; Rossi R; Riccardi C; Bistoni F
    J Med Microbiol; 1989 Nov; 30(3):183-92. PubMed ID: 2511321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunity to Candida.
    Fidel PL
    Oral Dis; 2002; 8 Suppl 2():69-75. PubMed ID: 12164664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Murine defense mechanism against Candida albicans infection. II. Opsonization, phagocytosis, and intracellular killing of C. albicans.
    Kagaya K; Fukazawa Y
    Microbiol Immunol; 1981; 25(8):807-18. PubMed ID: 7026987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dissociation between cell-mediated immunity and acquired resistance in systemic murine candidiasis.
    Hurtrel B; Lagrange PH
    Ann Inst Pasteur Immunol (1985); 1985; 136D(1):29-36. PubMed ID: 3933406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What's new in the mechanisms of host resistance to Candida albicans infection?
    Ashman RB; Papadimitriou JM
    Pathol Res Pract; 1990 Aug; 186(4):527-34. PubMed ID: 2247381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. I want to break free - macrophage strategies to recognize and kill Candida albicans, and fungal counter-strategies to escape.
    Austermeier S; Kasper L; Westman J; Gresnigt MS
    Curr Opin Microbiol; 2020 Dec; 58():15-23. PubMed ID: 32599492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired phagocytosis directs human monocyte activation in response to fungal derived β-glucan particles.
    Camilli G; Eren E; Williams DL; Aimanianda V; Meunier E; Quintin J
    Eur J Immunol; 2018 May; 48(5):757-770. PubMed ID: 29313961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorphonuclear leukocytes and macrophages.
    Jensen J; Warner T; Balish E
    J Infect Dis; 1993 Apr; 167(4):912-9. PubMed ID: 8383723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteomic characterization of human proinflammatory M1 and anti-inflammatory M2 macrophages and their response to Candida albicans.
    Reales-Calderón JA; Aguilera-Montilla N; Corbí ÁL; Molero G; Gil C
    Proteomics; 2014 Jun; 14(12):1503-18. PubMed ID: 24687989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phagocytosis and killing assays for Candida species.
    Du C; Calderone RA
    Methods Mol Biol; 2009; 499():17-26. PubMed ID: 19152035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages.
    Vazquez-Torres A; Jones-Carson J; Balish E
    Infect Immun; 1996 Aug; 64(8):3127-33. PubMed ID: 8757843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic Candidiasis and TLR2 Agonist Exposure Impact the Antifungal Response of Hematopoietic Stem and Progenitor Cells.
    Martínez A; Bono C; Megías J; Yáñez A; Gozalbo D; Gil ML
    Front Cell Infect Microbiol; 2018; 8():309. PubMed ID: 30234030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Candidiasis--do we need to fight or to tolerate the Candida fungus?
    Raska M; Bĕláková J; Krupka M; Weigl E
    Folia Microbiol (Praha); 2007; 52(3):297-312. PubMed ID: 17702470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection.
    Lehrer RI; Cline MJ
    J Clin Invest; 1969 Aug; 48(8):1478-88. PubMed ID: 5796360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of immunotherapy in invasive candidiasis: antifungal activity and cytokine expression assays.
    Simitsopoulou M; Roilides E
    Methods Mol Med; 2005; 118():161-79. PubMed ID: 15888942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunity to Candida albicans: Th1, Th2 cells and beyond.
    Romani L
    Curr Opin Microbiol; 1999 Aug; 2(4):363-7. PubMed ID: 10458979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.